Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine by binding to the phosphatidylserine-binding protein _2-glycoprotein 1 (_2GP1). Bavituximab has the potential for the treatment of cancers and viral infection.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.